Reclast (Zoledronic Acid) Pre-Surgery Hold Window: What Women Need to Know

Why the Pre-Surgery Hold Question Matters for Women

The hold question is not trivial. Most bisphosphonate research has been conducted in postmenopausal women, which means the data you are reading is, for once, largely generated in female bodies. Zoledronic acid is the most commonly prescribed IV bisphosphonate for postmenopausal osteoporosis, and women make up the overwhelming majority of the roughly 10 million Americans diagnosed with osteoporosis.

When a woman on Reclast is told she needs a hip replacement, a tooth extraction, or jaw reconstruction, the conversation about timing becomes genuinely complex. The drug's extraordinary skeletal retention means that simply "stopping" it before surgery does not flush it from bone. Understanding that mechanism is the foundation of every hold decision.

How Zoledronic Acid Behaves in Bone

Zoledronic acid binds to hydroxyapatite at sites of active bone remodeling. After a single 5 mg infusion, plasma concentration drops to near-undetectable levels within 24 hours, but skeletal retention persists for an estimated 10 years or longer. This means a "hold window" measured in weeks is pharmacologically meaningless. The drug remains pharmacologically active in bone regardless of whether the next annual dose is given.

That reality drives two separate clinical questions:

1. Does retained zoledronic acid in bone impair surgical healing or increase infection risk for general or orthopedic surgery?
2. Does it increase the risk of MRONJ when bone is surgically exposed in the jaw?

The answers are different for each, and conflating them leads to unnecessary treatment delays or, conversely, preventable complications.

HORIZON-PFT: The Trial Behind the Drug

The HORIZON-Key Fracture Trial (HORIZON-PFT), published in the New England Journal of Medicine in 2007, enrolled 7,765 postmenopausal women with osteoporosis and randomized them to 5 mg zoledronic acid IV annually versus placebo for three years. The result was a 70% reduction in new morphometric vertebral fractures and a 41% reduction in hip fractures compared with placebo. All-cause mortality was also reduced by 28% in the zoledronic acid arm, a finding that remains one of the most striking secondary outcomes in bisphosphonate research.

HORIZON-PFT enrolled only postmenopausal women, so the fracture-reduction data is directly applicable to the population most likely to be asking about this drug. The trial did not examine surgical outcomes or hold windows specifically, but it established the population-level safety profile that informs perioperative risk estimates.

General and Orthopedic Surgery: Is a Hold Actually Needed?

For most elective non-dental surgeries, including hip arthroplasty, knee replacement, spinal fusion, and abdominal procedures, there is no evidence-based mandatory pre-operative hold period for zoledronic acid.

What the Evidence Shows

Bisphosphonates theoretically could impair bone remodeling around orthopedic implants, but observational data from large joint-replacement registries have not confirmed a clinically significant increase in implant failure or delayed wound healing in patients on bisphosphonate therapy. A 2014 study in the Journal of Bone and Joint Surgery found no significant difference in periprosthetic fracture rate or revision rate in bisphosphonate users undergoing total hip arthroplasty.

For fracture repair surgery specifically, the evidence is more nuanced. Some animal-model data suggest bisphosphonates may slow early callus remodeling, but human clinical trials have not demonstrated meaningful delays in fracture union at therapeutic osteoporosis doses.

Practical Surgical Guidance for Orthopedic Cases

• If a woman is scheduled for elective joint replacement and her next annual Reclast infusion is due, deferring that infusion by 3-6 months is a reasonable, low-risk choice that avoids any theoretical perioperative concern without compromising long-term anti-fracture protection.
• If she has already received her infusion within the last 12 months, nothing changes perioperatively. The bone concentration is fixed regardless of timing.
• Emergency fracture surgery proceeds without any delay regardless of bisphosphonate history.

No guideline from the American College of Obstetricians and Gynecologists, the American Society for Bone and Mineral Research, or the American Academy of Orthopaedic Surgeons mandates a specific hold window for zoledronic acid before orthopedic procedures.

Dental and Jaw Surgery: The MRONJ Risk and the Real Hold Window

This is where the clinical calculus genuinely changes. Medication-related osteonecrosis of the jaw (MRONJ) is the primary reason a pre-procedure hold is ever formally discussed for bisphosphonates.

Defining MRONJ

MRONJ is exposed, necrotic bone in the maxillofacial region that persists for more than eight weeks in a patient taking antiresorptive medication, without a history of radiation therapy to the jaw. For IV zoledronic acid used in oncology (doses 4 mg every 3-4 weeks), MRONJ risk is substantial, ranging from 1% to 15% depending on duration of therapy. For the osteoporosis dose of 5 mg annually, the risk is far lower, estimated at 0.01% to 0.069% per patient-year, but it is not zero, and the consequences for affected women are severe.

What Triggers MRONJ

Invasive dental procedures that expose alveolar bone carry the highest risk:

• Tooth extractions (the leading precipitant)
• Dental implant placement
• Periapical surgery
• Osseous surgery for periodontal disease
• Jaw reconstruction

Routine fillings, root canals confined to the tooth, and non-surgical periodontal cleanings do not carry meaningful MRONJ risk and require no drug hold.

The Two-Year Guidance: Where It Comes From

The American Association of Oral and Maxillofacial Surgeons (AAOMS) 2022 position paper on MRONJ recommends that, for patients on oral or IV antiresorptive therapy for osteoporosis who require invasive dental procedures, clinicians consider a "drug holiday" of at least two years of no new antiresorptive dosing before elective jaw surgery, provided systemic health permits the pause. This two-year figure is not arbitrary. It reflects the time needed for bone surface turnover to begin recovering measurable resorption activity, as assessed by surrogate markers such as serum C-terminal telopeptide (CTX). The AAOMS also acknowledges that CTX levels <150 pg/mL have been associated with higher MRONJ risk, though CTX alone is an imperfect predictor and is no longer recommended as the sole decision tool.

For zoledronic acid specifically, the two-year hold means no new annual infusion for two consecutive cycles. The drug already present in bone from prior years cannot be removed, but allowing the antiresorptive burden to begin declining may reduce perioperative risk at the alveolar bone level.

Weighing the Fracture Risk of Stopping

A two-year pause is not without cost. Postmenopausal women who discontinue bisphosphonates see bone density begin to decline, though zoledronic acid's long skeletal half-life means the offset is slower than with oral agents. A HORIZON extension study showed bone mineral density remained above pre-treatment baseline for up to three years after stopping annual infusions. Still, a woman with a prior vertebral fracture and a T-score below minus 2.5 is not the same candidate for a two-year hold as a woman with a T-score of minus 1.8 and no fracture history.

The decision must be individualized. Your prescribing clinician, your oral surgeon, and your dentist need to communicate directly rather than issuing siloed recommendations.

Who This Is Right For, and Who Needs a Different Conversation

Women for Whom a Hold Is Clinically Reasonable

• Postmenopausal women on Reclast for 3 or fewer years with T-scores above minus 2.5 and no prior fragility fracture who need elective dental implants or jaw surgery
• Women who have achieved their BMD treatment target and are considering a planned drug holiday for other reasons, making the pre-dental hold an aligned decision

Women for Whom Stopping Zoledronic Acid Carries Meaningful Risk

• Women with a prior hip or vertebral fragility fracture
• Women with T-scores at or below minus 3.0
• Women with secondary osteoporosis from glucocorticoid use or aromatase inhibitor therapy for breast cancer (a growing population with high fracture risk)
• Women in early postmenopause with rapid bone loss

For these women, the dental procedure should be timed around the drug rather than the reverse. Extracting a tooth can often be done with conservative surgical technique, primary wound closure, and antiseptic rinses to reduce MRONJ risk without stopping the bisphosphonate.

Life-Stage Considerations Across the Spectrum

Postmenopausal women (the primary population). The hold conversation described throughout this article applies here. Fracture risk must be weighed against MRONJ risk in a shared-decision framework.

Perimenopausal women. Zoledronic acid is not typically started until menopause is confirmed or bone loss is documented. If a perimenopausal woman is on it for secondary osteoporosis (e.g., from long-term corticosteroids or premature ovarian insufficiency), the same hold framework applies.

Women of reproductive age. Zoledronic acid should not be used and is almost never prescribed in this group. See the pregnancy section below for why.

Pregnancy, Lactation, and Contraception: A Required Disclosure

Zoledronic acid is contraindicated in pregnancy. This is non-negotiable.

Pregnancy Safety

Animal reproductive studies demonstrate fetal skeletal abnormalities, delayed ossification, and hypocalcemia with bisphosphonate exposure. No adequate human trials exist because the drug is appropriately never given to pregnant women. The FDA classifies zoledronic acid as Pregnancy Category D under the legacy system, meaning positive evidence of fetal risk. Under the current Pregnancy and Lactation Labeling Rule (PLLR), the label states the drug may cause fetal harm based on animal data and theoretical mechanism.

Bisphosphonates incorporate into fetal skeleton from maternal bone stores and can theoretically remain there. Because zoledronic acid has a skeletal half-life exceeding 10 years, any woman of reproductive potential who receives this drug should be counseled that trace skeletal retention may persist through a future pregnancy even years later. This theoretical risk has not been quantified in prospective human data, which is an evidence gap that must be named honestly.

Contraception Requirement

Any woman of childbearing potential who is prescribed zoledronic acid (a rare but real scenario in premature ovarian insufficiency or glucocorticoid-induced osteoporosis) should use effective contraception during treatment. If pregnancy occurs, the drug must be discontinued and the patient referred to maternal-fetal medicine for counseling.

Lactation

Zoledronic acid transfer into human breast milk has not been studied. Given the drug's mechanism and the potential for infant skeletal exposure, breastfeeding is not recommended during zoledronic acid treatment. This is primarily a precautionary recommendation based on the absence of safety data rather than documented harm.

Monitoring Before and After Surgery

Pre-Infusion Dental Clearance

The most evidence-supported perioperative intervention for women on Reclast is preventive dentistry before starting the drug, not after. The American Dental Association and AAOMS both recommend that clinicians perform a comprehensive oral exam and complete any indicated extractions or surgical dental work at least four weeks before a patient's first bisphosphonate infusion. This window allows initial alveolar healing before the drug is present in jaw bone.

If your patient is already on Reclast and has not had this baseline dental evaluation, schedule one now. Catching a failing tooth early avoids an urgent extraction under far less favorable circumstances.

Lab Markers Worth Knowing

• Serum creatinine and eGFR. Zoledronic acid is renally cleared; it is contraindicated in women with creatinine clearance <35 mL/min. Renal function should be checked before each annual infusion.
• Serum calcium and 25-OH vitamin D. Hypocalcemia is the most common acute adverse event. Women should have vitamin D repletion confirmed (ideally 25-OH D >30 ng/mL) before infusion.
• CTX (C-terminal telopeptide). As noted above, this marker of bone resorption activity is sometimes used to gauge antiresorptive burden before jaw surgery. Values are highly dependent on fasting status and time of day, so standardize collection conditions. A fasting morning CTX below 100-150 pg/mL is considered by some oral surgeons to indicate higher MRONJ risk, but current evidence does not support CTX as a standalone gating criterion for proceeding with or delaying dental surgery.

Post-Infusion Acute Reaction

About 30% of women experience an acute-phase reaction within 24-72 hours of the first zoledronic acid infusion: flu-like symptoms, myalgia, low-grade fever. This is immune-mediated and largely confined to the first infusion. It has no bearing on surgical planning but is worth anticipating so women are not alarmed.

The Evidence Gap: What We Still Do Not Know

Women have historically been enrolled in osteoporosis trials at high rates (HORIZON-PFT is a good example), but the surgical and perioperative data are weaker. Specifically:

• No randomized controlled trial has examined the optimal hold window before invasive dental procedures for women on IV bisphosphonates at osteoporosis doses.
• The two-year dental hold recommendation is based on expert consensus and case series, not prospective RCT data.
• Women with aromatase-inhibitor-associated bone loss or breast-cancer-related bisphosphonate use represent a distinct population that has been studied in breast-cancer trials but not in dedicated perioperative dental-safety studies.

When your provider tells you to wait two years before a dental implant, they are giving you the best current guidance, but that guidance rests on lower-quality evidence than you might assume.

Practical Checklist: Before Your Next Procedure

Use this framework with your care team:

For any elective orthopedic or general surgery:

• No mandatory zoledronic acid hold is required by current guidelines.
• Consider deferring the next annual infusion by 3-6 months if surgery is scheduled and the infusion date coincides.
• Ensure renal function is current before the next infusion regardless of surgery.

For elective invasive dental procedures (extractions, implants, jaw surgery):

• Discuss with your prescribing physician whether a hold of 12-24 months before the procedure is appropriate given your fracture risk profile.
• Complete urgent or necessary dental work as conservatively as possible without waiting.
• After the dental procedure heals (typically 2-3 months of mucosal healing), the conversation about restarting Reclast should happen proactively.

For urgent dental emergencies:

• Do not delay treatment for a dental infection or abscess. Acute infection poses greater jaw risk than proceeding with bisphosphonate on board.
• Inform your oral surgeon or dentist that you are on Reclast so they can use conservative closure techniques and appropriate antibiotics.

The annual infusion schedule gives your care team a natural annual checkpoint to revisit your fracture risk, your dental health, and whether the current treatment intensity still matches your needs. The Menopause Society's 2021 position statement on osteoporosis management recommends reassessing bisphosphonate therapy at 3-5 years for women at low-to-moderate fracture risk, and this reassessment is the ideal moment to align dental and surgical planning.